Raymond W. Cohen, Chief Executive Officer

RCohen

Raymond W. Cohen

Chief Executive Officer

Mr. Cohen is an accredited public company director with over 30 years of experience in leading medical device companies and serving on the boards at a number of private and publicly traded life science companies. From 2010 to 2012, he served as CEO of privately-held venture capital backed Vessix Vascular which was acquired by Boston Scientific in November 2012. He spent nearly a decade as Chairman & CEO of Nasdaq-listed Cardiac Science Inc. ranked as the 4th fastest growing company in U.S. in 2004. Currently, Mr. Cohen serves as the Chairman of the board of directors at Seattle-based BioLife Solutions (Nasdaq: BLFS – preservation media for human cells), UK-based Lombard Medical (Nasdaq: EVAR – endovascular AAA stent graft), UK-based Dysis Medical (system for detecting cervical cancer). He also serves as an independent director, chairman of the compensation committee and member of the audit committee of Henderson, NV and Irvine, CA-based Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI – Oncology drugs). Mr. Cohen also served on the boards of two firms that successfully executed an exit transaction in 2017, Zurich-based LifeWatch (LIFE.SW) sold to Biotelemetry (Nasdaq: BEAT) and Westminster, CO-based privately held Syncroness, Inc. (contract engineering) sold to ALTEN Group, a French multi-billion dollar engineering services company.

Dan L. Dearen, Chief Operating & Financial Officer

DD2

Dan L. Dearen

Chief Operating & Financial Officer

Mr. Dearen has over 20 years of experience in medical devices and pharmaceutical industries. Previously Chief Operating and Financial Officer at Vessix Vascular, Mr. Dearen was responsible for integration following the acquisition of Vessix by Boston Scientific. Prior to that, Mr. Dearen was CFO of a number of life science and venture capital firms including Miraval Holding, Q3DM, Fairbanks Systems Group, ESI Software, Medication Delivery Devices and positions with Ventana Growth Funds.

Prabodh Mathur, Chief Product Development Officer

PM2

Prabodh Mathur

Chief Product Development Officer

Mr. Mathur has over 25 years experience in developing Class III therapeutic medical devices. He previously led product development efforts for Boston Scientific, Vessix Vascular, Cardiac Science and Medstone Intl.

Guangqiang (Jay) Jiang, Ph.D., Chief Technology Officer

GJ2

Guangqiang (Jay) Jiang, Ph.D.

Chief Technology Officer

Dr. Jiang is a seasoned technical executive with a 15-year track record of developing complex, implantable Class III medical devices. He was previously VP of R&D at the Alfred Mann Foundation. Dr Jiang was elected to the American Institute for Medical and Biological Engineering (AIMBE)’s College of Fellows and served as Principal Investigator on several government contracts. Dr Jiang holds a Ph.D. in Biomedical Engineering from the University of Southern California.

Karen Noblett, M.D., Chief Medical Officer

Karen headshot

Karen Noblett, M.D.

Chief Medical Officer

Dr Noblett is Board Certified in OB/GYN and in Female Pelvic Medicine and Reconstructive Surgery. Before joining Axonics, she had a long career in academic medicine. She served as the founding Chair and Professor of the Department of OB/GYN in the School of Medicine at the University of California, Riverside from 2014-2017. Prior to this, she was a Professor in the OB/GYN Department and Fellowship and Division Director for Urogynecology at the University of California, Irvine, as well as the Interim Chief Medical officer.

Dr Noblett completed her Master of Advanced Studies in Clinical Research from UCSD. She has published over 50 peer-reviewed journal articles and authored multiple book chapters. She is a recognized expert in the field of sacral neuromodulation.

Michael V. Williamson, Esq., Sr. Vice President, General & IP Counsel

MW2

Michael V. Williamson, Esq.

Sr. Vice President, General & IP Counsel

Mr. Williamson is a lawyer and mechanical engineer by training. He was previously General & IP and counsel at Vessix Vascular. Expert in medical device intellectual property, legal transactions, regulatory, product development and operations, Mr. Williamson worked previously at Cordis Corporation/Nitinol Devices and Components.

Michael V. Williamson, Esq.

Sr. Vice President, General & IP Counsel

Mr. Williamson is a lawyer and mechanical engineer by training. He was previously General & IP and counsel at Vessix Vascular. Expert in medical device intellectual property, legal transactions, regulatory, product development and operations, Mr. Williamson worked previously at Cordis Corporation/Nitinol Devices and Components.

Rinda Sama, Vice President, Operations and Quality

RS2

Rinda Sama

Vice President, Operations and Quality

Mr. Sama brings more than 10 years of Class III medical device experience implementing lean Operations and compliant Quality Systems. Prior to Axonics, Mr. Sama was the Director of Operations and Quality at Vessix Vascular Inc., and then the Director of Program Management at Boston Scientific. Mr. Sama holds a Master’s degree in Biomedical Engineering from University of Southern California and an MBA from University of California, Irvine.

John Woock, Ph.D., Vice President, Global Marketing and Clinical Operations

JW2

John Woock, Ph.D.

Vice President, Global Marketing and Clinical Operations

Dr. Woock has a Ph.D. in Biomedical Engineering from Duke University, focused on neural stimulation to control urinary function. He is the co-inventor of several technologies in the field of urology. Dr Woock was previously a Stanford Biodesign Fellow and an Engagement Manager at McKinsey & Company.

Rabih Nassif, Vice President, Electrical Engineering

RN2

Rabih Nassif

Vice President, Electrical Engineering

Mr. Nassif brings over 30 years of product development experience, mainly in the field of medical devices. He has been a creative force through his previous leadership roles at Carefusion, Cardiac Science and Vessix Vascular.

Emilie Finiels, Senior Director, Business Development and Market Access

EF2

Emilie Finiels

Senior Director, Business Development and Market Access

Mrs. Finiels brings 5 years experience from the venture capital industry. She was previously an Associate at Edmond de Rothschild Investment Partners, where she worked on medical devices and biotech investments. Mrs. Finiels holds a MSc in Biochemistry from the University of Montpellier, France and the University of Oxford, and a MSc in Management from EMLyon Business School.